1
|
El Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. e12612012.https://doi.org/10.1053/j.gastro.2011.12.061
View Article : Google Scholar : PubMed/NCBI
|
2
|
Lozano-Sepulveda SA, Bryan-Marrugo OL,
Cordova-Fletes C, Gutierrez-Ruiz MC and Rivas-Estilla AM: Oxidative
stress modulation in hepatitis C virus infected cells. World J
Hepatol. 7:2880–2889. 2015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Romero-Gómez M: Insulin resistance and
hepatitis C. World J Gastroenterol. 12:7075–7080. 2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
García-Montalvo BM and Macossay-Castillo
M: Preliminary data for genotype distribution and epidemiological
aspects of hepatitis C virus infection in blood donors from
Yucatan, Mexico. Transfus Med. 17:488–490. 2007. View Article : Google Scholar : PubMed/NCBI
|
5
|
Koike K, Tsutsumi T, Yotsuyanagi H and
Moriya K: Lipid metabolism and liver disease in hepatitis C viral
infection. Oncology. 78 Suppl 1:24–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Chang ML: Metabolic alterations and
hepatitis C From bench to bedside. World J Gastroenterol.
22:1461–1476. 2016. View Article : Google Scholar : PubMed/NCBI
|
7
|
Sheikh MY, Choi J, Qadri I, Friedman JE
and Sanyal AJ: Hepatitis C virus infection: Molecular pathways to
metabolic syndrome. Hepatology. 47:2127–2133. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Milner KL, Jenkins AB, Trenell M, Tid-Ang
J, Samocha-Bonet D, Weltman M, Xu A, George J and Chisholm DJ:
Eradicating hepatitis C virus ameliorates insulin resistance
without change in adipose depots. J Viral Hepat. 21:325–332. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Bose SK and Ray R: Hepatitis C virus
infection and insulin resistance. World J Diabetes. 5:52–58. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Parvaiz F, Manzoor S, Tariq H, Javed F,
Fatima K and Qadri I: Hepatitis C virus infection: Molecular
pathways to insulin resistance. Virol J. 8:4742011. View Article : Google Scholar : PubMed/NCBI
|
11
|
Kim KA, Lin W, Tai AW, Shao RX, Weinberg
E, De Sa Borges CB, Bhan AK, Zheng H, Kamegaya Y and Chung RT:
Hepatic SOCS3 expression is strongly associated with non-response
to therapy and race in HCV and HCV/HIV infection. J Hepatol.
50:705–711. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Banerjee A, Meyer K, Mazumdar B, Ray RB
and Ray R: Hepatitis C virus differentially modulates activation of
forkhead transcription factors and insulin-induced metabolic gene
expression. J Virol. 84:5936–5946. 2010. View Article : Google Scholar : PubMed/NCBI
|
13
|
Deltenre P, Louvet A, Lemoine M, Mourad A,
Fartoux L, Moreno C, Henrion J, Mathurin P and Serfaty L: Impact of
insulin resistance on sustained response in HCV patients treated
with pegylated interferon and ribavirin: A meta-analysis. J
Hepatol. 55:1187–1194. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mason AL, Lau JY, Hoang N, Qian K,
Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, et
al: Association of diabetes mellitus and chronic hepatitis C virus
infection. Hepatology. 29:328–333. 1999. View Article : Google Scholar : PubMed/NCBI
|
15
|
Bose SK, Shrivastava S, Meyer K, Ray RB
and Ray R: Hepatitis C virus activates the mTOR/S6K1 signaling
pathway in inhibiting IRS-1 function for insulin resistance. J
Virol. 86:6315–6322. 2012. View Article : Google Scholar : PubMed/NCBI
|
16
|
Deng L, Shoji I, Ogawa W, Kaneda S, Soga
T, Jiang DP, Ide YH and Hotta H: Hepatitis C virus infection
promotes hepatic gluconeogenesis through an NS5A-mediated,
FoxO1-dependent pathway. J Virol. 85:8556–8568. 2011. View Article : Google Scholar : PubMed/NCBI
|
17
|
Knobler H and Malnick S: Hepatitis C and
insulin action: An intimate relationship. World J Hepatol.
8:131–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Romero-Gómez M, Del Mar Viloria M, Andrade
RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M,
Grande L, Vázquez L, et al: Insulin resistance impairs sustained
response rate to peginterferon plus ribavirin in chronic hepatitis
C patients. Gastroenterology. 128:636–641. 2005. View Article : Google Scholar : PubMed/NCBI
|
19
|
De Bandt JP and Cynober L: Therapeutic use
of branched-chain amino acids in burn, trauma, and sepsis. J Nutr.
136:308S–313S. 2006.PubMed/NCBI
|
20
|
Wullschleger S, Loewith R and Hall MN: TOR
signaling in growth and metabolism. Cell. 124:471–484. 2006.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Averous J and Proud CG: When translation
meets transformation: The mTOR story. Oncogene. 25:6423–6435. 2006.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Nobukuni T, Kozma SC and Thomas G: hvps34,
an ancient player, enters a growing game: mTOR Complex1/S6K1
signaling. Curr Opin Cell Biol. 19:135–141. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Abad-Lacruz A, Cabré E, González-Huix F,
Fernández-Bañares F, Esteve M, Planas R, Llovet JM, Quer JC and
Gassull MA: Routine tests of renal function, alcoholism, and
nutrition improve the prognostic accuracy of Child-Pugh score in
nonbleeding advanced cirrhotics. Am J Gastroenterol. 88:382–387.
1993.PubMed/NCBI
|
24
|
Blonde-Cynober F, Aussel C and Cynober L:
Abnormalities in branched-chain amino acid metabolism in cirrhosis:
Influence of hormonal and nutritional factors and directions for
future research. Clin Nutr. 18:5–13. 1999. View Article : Google Scholar : PubMed/NCBI
|
25
|
Okuno M, Moriwaki H, Kato M, Muto Y and
Kojima S: Changes in the ratio of branched-chain to aromatic amino
acids affect the secretion of albumin in cultured rat hepatocytes.
Biochem Biophys Res Commun. 214:1045–1050. 1995. View Article : Google Scholar : PubMed/NCBI
|
26
|
She P, Reid TM, Bronson SK, Vary TC,
Hajnal A, Lynch CJ and Hutson SM: Disruption of BCATm in mice leads
to increased energy expenditure associated with the activation of a
futile protein turnover cycle. Cell Metab. 6:181–194. 2007.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Korenaga K, Korenaga M, Uchida K, Yamasaki
T and Sakaida I: Effects of a late evening snack combined with
alpha-glucosidase inhibitor on liver cirrhosis. Hepatol Res.
38:1087–1097. 2008. View Article : Google Scholar : PubMed/NCBI
|
28
|
Sakaida I, Tsuchiya M, Okamoto M and Okita
K: Late evening snack and the change of blood glucose level in
patients with liver cirrhosis. Hepatol Res. 30S:1–72.
2004.PubMed/NCBI
|
29
|
Kawaguchi T, Nagao Y, Matsuoka H, Ide T
and Sata M: Branched-chain amino acid-enriched supplementation
improves insulin resistance in patients with chronic liver disease.
Int J Mol Med. 22:105–112. 2008.PubMed/NCBI
|
30
|
Kawaguchi T, Taniguchi E, Itou M, Sumie S,
Oriishi T, Matsuoka H, Nagao Y and Sata M: Branched-chain amino
acids improve insulin resistance in patients with hepatitis C
virus-related liver disease: Report of two cases. Liver Int.
27:1287–1292. 2007.PubMed/NCBI
|
31
|
Syed GH, Amako Y and Siddiqui A: Hepatitis
C virus hijacks host lipid metabolism. Trends Endocrinol Metab.
21:33–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
32
|
Amako Y, Munakata T, Kohara M, Siddiqui A,
Peers C and Harris M: Hepatitis C virus attenuates mitochondrial
lipid β-oxidation by downregulating mitochondrial
trifunctional-protein expression. J Virol. 89:4092–4101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
33
|
Ramcharran D, Wahed AS, Conjeevaram HS,
Evans RW, Wang T, Belle SH and Yee LJ: Serum lipids and their
associations with viral levels and liver disease severity in a
treatment-naïve chronic hepatitis C type 1-infected cohort. J Viral
Hepat. 18:e144–e152. 2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Gross CR, Malinchoc M, Kim WR, Evans RW,
Wiesner RH, Petz JL, Crippin JS, Klintmalm GB, Levy MF, Ricci P, et
al: Quality of life before and after liver transplantation for
cholestatic liver disease. Hepatology. 29:356–364. 1999. View Article : Google Scholar : PubMed/NCBI
|
35
|
Kawamura N, Nakajima H and Takashi SI:
Administration of granulated BCAA and quality of life. Hepatol Res.
30S:1–45. 2004.PubMed/NCBI
|
36
|
Kawaguchi T, Taniguchi E and Sata M:
Effects of oral branched-chain amino acids on hepatic
encephalopathy and outcome in patients with liver cirrhosis. Nutr
Clin Pract. 28:580–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Levy JC, Matthews DR and Hermans MP:
Correct homeostasis model assessment (HOMA) evaluation uses the
computer program. Diabetes Care. 21:2191–2192. 1998. View Article : Google Scholar : PubMed/NCBI
|
38
|
Hernández Yero JA, Tuero Iglesias Á and
Vargas González D: Utilidad del índice HOMA IR con una sola
determinación de insulinemia para diagnosticar resistencia
insulínica. Rev Cuba Endocrinol. 22:69–77. 2011.
|
39
|
Buccini GS and Wolfthal DL: Valores de
corte para índices de insulinorresistencia, insulinosensibilidad e
insulinosecreción derivados de la fórmula HOMA y del programa
HOMA2: Interpretación de los datos. Revista argentina de
endocrinología y metabolismo. 45:03 212008.
|
40
|
Vilagut G, Ferrer M, Rajmil L, Rebollo P,
Permanyer-Miralda G, Quintana JM, Santed R, Valderas JM, Ribera A,
Domingo-Salvany A, et al: El Cuestionario de Salud SF-36 español:
Una década de experiencia y nuevos desarrollos. Gac Sanit.
19:135–150. 2005. View
Article : Google Scholar : PubMed/NCBI
|
41
|
Garrouste-Orgeas M, Troché G, Azoulay E,
Caubel A, de Lassence A, Cheval C, Montesino L, Thuong M, Vincent
F, Cohen Y, et al: Body mass index. An additional prognostic factor
in ICU patients. Intensive Care Med. 30:437–443. 2004. View Article : Google Scholar : PubMed/NCBI
|
42
|
Rouvière O, Yin M, Dresner MA, Rossman PJ,
Burgart LJ, Fidler JL and Ehman RL: MR elastography of the liver:
Preliminary results. Radiology. 240:440–448. 2006. View Article : Google Scholar : PubMed/NCBI
|
43
|
Bota S, Sirli R, Sporea I, Focsa M,
Popescu A, Danila M, Strain M, Sendroiu M, Deleanu A and Dan I: A
new scoring system for prediction of fibrosis in chronic hepatitis
C. Hepat Mon. 11:548–555. 2011.PubMed/NCBI
|
44
|
Gluud C, Conn HO and Eriksson LS:
Branched-chain amino acids for hepatic encephalopathy? Hepatology.
13:812–813. 1991. View Article : Google Scholar : PubMed/NCBI
|
45
|
Charlton M: Branched-chain amino acid
enriched supplements as therapy for liver disease. J Nutr.
136:295S–298S. 2006.PubMed/NCBI
|
46
|
Chen L, Chen Y, Wang X, Li H, Zhang H,
Gong J, Shen S, Yin W and Hu H: Efficacy and safety of oral
branched-chain amino acid supplementation in patients undergoing
interventions for hepatocellular carcinoma: A meta-analysis. Nutr
J. 14:672015. View Article : Google Scholar : PubMed/NCBI
|
47
|
Muto Y, Sato S, Watanabe A, Moriwaki H,
Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, et
al Long-Term Survival Study Group, : Effects of oral branched-chain
amino acid granules on event-free survival in patients with liver
cirrhosis. Clin Gastroenterol Hepatol. 3:705–713. 2005. View Article : Google Scholar : PubMed/NCBI
|
48
|
Higuchi N, Kato M, Miyazaki M, Tanaka M,
Kohjima M, Ito T, Nakamuta M, Enjoji M, Kotoh K and Takayanagi R:
Potential role of branched-chain amino acids in glucose metabolism
through the accelerated induction of the glucose-sensing apparatus
in the liver. J Cell Biochem. 112:30–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
49
|
Adeva MM, Calviño J, Souto G and Donapetry
C: Insulin resistance and the metabolism of branched-chain amino
acids in humans. Amino Acids. 43:171–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
50
|
Knowler WC, Narayan KM, Hanson RL, Nelson
RG, Bennett PH, Tuomilehto J, Scherstén B and Pettitt DJ:
Preventing non-insulin-dependent diabetes. Diabetes. 44:483–488.
1995. View Article : Google Scholar : PubMed/NCBI
|
51
|
Takeshita Y, Takamura T, Kita Y, Ando H,
Ueda T, Kato K, Misu H, Sunagozaka H, Sakai Y, Yamashita T, et al:
Beneficial effect of branched-chain amino acid supplementation on
glycemic control in chronic hepatitis C patients with insulin
resistance: Implications for type 2 diabetes. Metabolism.
61:1388–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|